Filing Flows › Insight Molecular Diagnostics (IMDX) › Q2 2025
Insight Molecular Diagnostics (IMDX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Insight Molecular Diagnostics (IMDX) reported revenue of $518K for the second quarter 2025 (Q2 2025), +398% from a year earlier and -76% from the quarter before.
Insight Molecular Diagnostics, Q2 2025: revenue $518K (+398% year over year), net loss $9.7M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $518K | -76% | +398% |
| Operating profit | −$9.8M | — | — |
| Net earnings | −$9.7M | — | — |
| Operating cash flow | −$6.2M | — | — |
What changed
Revenue was $518K in Q2 2025, up 398% year over year and down 76% from the previous quarter. Laboratory Services was the largest line at 95% of revenue. Laboratory Services added $390K year over year (up 375%), 94% of the total change.
Gross margin was 65.3%, up 17.2 points from a year earlier. Operating costs exceeded revenue by $9.8M, an operating margin of -1900.0%. Operating expenses grew 117% against revenue growth of 398%. The quarter ended with a net loss of $9.7M, wider than the previous quarter's $6.7M loss.
Operating cash flow was −$6.2M. Non-cash charges added back $559K of depreciation and amortization and $504K of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $349K exceeded it, leaving free cash flow of −$6.5M.
Questions
What was Insight Molecular Diagnostics' revenue in the second quarter 2025?
Insight Molecular Diagnostics (IMDX) reported revenue of $518K for the second quarter 2025 (Q2 2025), +398% from a year earlier and -76% from the quarter before.